Skip to content

Studying Infant Nutrition and Blood Sugar

Studying Infant Nutrition and Glycemia (SING)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03524469
Enrollment
156
Registered
2018-05-14
Start date
2018-06-01
Completion date
2024-12-01
Last updated
2024-12-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insulin Resistance, Obesity

Brief summary

The purpose of this study is to learn about how breast milk from mothers with insulin-resistance may be different. Investigators are specifically studying insulin concentrations in breast milk. Investigators are also studying how insulin in breast milk might affect a baby's intestines and pancreas.

Interventions

None listed

Sponsors

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
CollaboratorNIH
The Gerber Foundation
CollaboratorOTHER
University of Rochester
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Mothers ≥ 19 years of age * Mothers intending to Exclusively Breastfeed for at least 5months * Mothers comfortable with feeding their infants expressed breast milk from a bottle at 2-weeks postpartum * Trial of labor (no scheduled C-sections) * Singleton birth * Healthy Infants * Normal Weight will be defined as pre-pregnant BMI between 18.5-23.9 kg/m2 and passing the 28 week oral glucose tolerance test. * Insulin Resistance will be defined as meeting any of the following: * pre-pregnant BMI ≥ 28 and failed the 28 week oral glucose screening test * pre-pregnant BMI ≥ 28 and diagnosis of either A1 (diet controlled) or A2 (insulin-requiring) gestational diabetes during pregnancy, but insulin therapy discontinued after birth. * pre-pregnant BMI ≥ 28 and diagnosed with type 2 diabetes during pregnancy * pre-pregnant BMI ≥ 30, and unmediated.

Exclusion criteria

* Scheduled C-sections or emergency C-sections with no labor (natural or induced) * Maternal insulin therapy after birth * Significant maternal health concern including type 1 diabetes, renal, kidney, thyroid, or cardiovascular disease, pre-eclampsia, or other disease. * Delivery before 37 weeks * Infant birth weight \<2500g * Infant medical or genetic indications that would impact normal feeding behavior, insulin signaling or growth patterns * Infant supplementation with infant formula (glucose gel or donor milk is acceptable)

Design outcomes

Primary

MeasureTime frameDescription
mean infant postprandial C peptide to creatinine ratio2 weeksPostprandial urine (60-90 minute) will be tested for C peptide and creatinine and the ratio will be calculated.

Secondary

MeasureTime frameDescription
mean infant insulinogenic index5 monthsThe insulinogenic index will be measures in infant blood at 0 and 30 minutes post glucose administration. The index is the change in insulin over the change in glucose.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026